0
2022
Leukapheresis Market

Leukapheresis Market

by Product (Devices, Disposables), by Method (Centrifugation, Membrane Separation, Selective Adsorption), by Application (Therapeutic Applications, Research Applications), by End User (Blood Centers, Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031

Report Code: A09084
Oct 2022 | Pages: 274
Tables: 152
Charts: 61
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Leukapheresis Market Research, 2031

The global leukapheresis market size was valued at $245.7 million in 2021, and is projected to reach $561.6 million by 2031, growing at a CAGR of 8.6% from 2022 to 2031. Leukapheresis is laboratory procedure in which white blood cells are separated from sample of blood. It can be used for to lower an extremely high white blood cell count, to extract autologous or allogeneic blood cells for subsequent transplantation into the patient or for research purposes.

The leukapheresis is used in treatment of leukemia or patients with high white blood cells. In the case of hematological malignancies such as chronic leukemias, white blood cell counts may be high enough to cause leukostasis (acute leukemias have a more variable white cell count and chronic cases typically have higher white blood cell counts). This can affect vision changes, shortness of breath from decreased efficiency in oxygen exchange, as well as other organ systems. Thus, leukapheresis may be performed to obtain the patient's own blood cells for a later transplant. Leukapheresis, is typically for granulocytes, is a rarely performed in blood donation process.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global leukapheresis market as leukapheresis products was benefited from the COVID-19, as the vaccines which were undergoing clinical testing included the research on white blood cells.

Leukapheresis Market

Increase in prevalence of leukemia is the key factor that drives the growth of the global leukapheresis market size. For instance, according to National Library of Medicine in China 2022, is estimated the approximately 88,249 new cases of leukemia (50,213 male cases and 38,036 female cases). In addition, increase in number of clinical trials and increase in public and private investments for the development of CAR (chimeric antigen receptor)-T therapy in which leukapheresis is the first step for CAR-T therapy drive the market growth. However, high cost associated with leukapheresis therapeutics and leukopak and blood transfusion safety in developing countries may hinder the market growth. In contrast increase in demand for leukapheresis in pediatric patients are anticipated to provide lucrative leukapheresis market opportunity to the market players.

Impact of COVID-19

The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, COVID-19 pandemic positively impacted the leukapheresis industry.

Leukapheresis is a laboratory procedure in which white blood cells are separated from the blood. One symptom of COVID-19 is a reduction in the number of lymphocytes cells in the blood. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. For instance, in May 2020, the National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID) initiated a clinical study to identify how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system using the leukapheresis technique by collecting white blood cells from the patients who recovered from COVID-19.

LEUKAPHERESIS MARKET SEGMENTATION

The leukapheresis market is segmented into product, method, application, end user and region. By product, the market is categorized into devices and disposables. By method, it is classified into centrifugation, membrane separation, and selective adsorption. By application, the market is classified into therapeutics application and research application. On the basis of end user, the market is categorized into blood centers, hospitals, and others. Others segment further includes research institutes, biopharmaceutical manufacturers, and private medical settings. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Depending on product, the market is segmented into devices and disposables. The disposables segment was dominated the leukapheresis market share in 2021 and is remain dominant during the leukapheresis market forecast period. The major factor which drives the growth of this segment include, rise in demand for leukapheresis disposables due to rise in prevalence of leukemia which fuel the segment growth. For instance, according to Cancer Research UK, (2017-2019), leukemia is the 12th most common cause of cancer death with around 2,000 deaths every year in females. In addition, advantage associated with disposable leukapheresis such as it reduces the risk of infection during transfusion of blood which fuels the segmental growth.

Leukapheresis Market
By Product

Your browser does not support the canvas element.

The disposables segment held largest share in the global market in 2021.

Get more information on this report : Request Sample Pages

On the basis of method, the market is segmented into centrifugation, membrane separation, and selective adsorption. The centrifugation segment was accounted for the largest revenue in 2021. This was attributed to increase in installation of centrifugal apheresis devices in hospitals for therapeutic leukapheresis. In addition, rise in utilized leukapheresis equipment developed by key market players perform leukocyte separation using centrifugation. For instance, spectra optia apheresis system developed by Terumo BCT.

However, the membrane separation segment is projected to register highest CAGR during the forecast period. This is attributed to rise in adoption of membrane separation leukapheresis due to increase in prevalence of leukemia which boost the leukapheresis industry.

Leukapheresis Market
By Method

Your browser does not support the canvas element.

The centrifugation segment held largest market share in 2021. However, membrane separation segment is anticipated to grow at the highest CAGR of 9.3% during the forecast period.

Get more information on this report : Request Sample Pages

On the basis of application, the market is segmented into therapeutics application and research application. Therapeutics application segment was accounted for the largest revenue in 2021. This was attributed to strong network of the therapeutic leukapheresis service providers across the globe.

In addition, rise in geriatric population with leukemia cancer has increased the demand for leukapheresis procedure in hospitals which drive the market growth. For instance, according to the World Population Ageing report (2020), in South Korea, the population aged 65 years or over is expected to reach 5,232,000 (19.7%) of the total population in 2050 from 2,376,000 (9.3%) of the total population in 2019. Thus, increase in geriatric population is likely to require more leukapheresis procedure as it is prone to chronic disorders.

Leukapheresis Market
By Application

Your browser does not support the canvas element.

The therapeutics application segment dominated the market in 2021. However, research application segment is expected to grow at a CAGR of 9.1% during the forecast period.

Get more information on this report : Request Sample Pages

On the basis of end user, the market is segmented into blood centers, hospitals and others. Others segment further includes research institutes, biopharmaceutical manufacturers, and private medical settings. The blood centers segment dominated the market in 2021. This was attributed to increase in the promotional activities performed by blood centers towards blood donation. In addition, increase in demand for blood components in clinical conditions such as cancer drive the blood centers segment growth. For instance, according to the Red Cross Blood Organization, the number of blood donors is 6.8 million a year in the U.S., and approximately 36,000 units of blood are required every day in the country.

Leukapheresis Market
By End User

Your browser does not support the canvas element.

The blood centers segment dominated the market in 2021. However, others segment is anticipated to grow at the highest CAGR of 9.3% during the forecast period.

Get more information on this report : Request Sample Pages

Region wise, North America acquired a leukapheresis market share, owing to the presence of key players, rise in government initiatives, well-developed healthcare infrastructure, and increase in prevalence of leukemia. In addition, advanced technology for leukapheresis further boost the market growth.

However, Asia-Pacific is expected to witness the highest growth rate for the leukapheresis market throughout the forecast period. The major factors that drive the growth of the leukapheresis market in this region is the increase in prevalence of leukemia in this region. In addition, technological advancements, and increase in government initiatives to promote healthy lifestyle are driving the market growth. Moreover rise in number of hospitals and blood centers for leukapheresis in this region further boost the leukapheresis market growth.

Leukapheresis Market
By Region

2031
North America 
Europe
Asia-Pacific
LAMEA

North America held largest share in the global market in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 10.1% during the forecast period.

Get more information on this report : Request Sample Pages

 
The key market players profiled in the report include are Adacyte Therapeutics, AllCells, LLC, Asahi Kasei Corporation, Cerus Corporation, Charles River Laboratories International, Inc. Fresenius Kabi, Haemonetics Corporation, Macopharma, SB-Kawasumi Laboratories, Inc. and Terumo BCT, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the leukapheresis market analysis from 2021 to 2031 to identify the prevailing leukapheresis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the leukapheresis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global leukapheresis market trends, key players, market segments, application areas, and market growth strategies.

Leukapheresis Market Report Highlights

Aspects Details
Market Size By 2031 USD 561.6 million
Growth Rate CAGR of 8.6%
Forecast period 2021 - 2031
Report Pages 274
By Product
  • Devices
  • Disposables
By Method
  • Centrifugation
  • Membrane Separation
  • Selective Adsorption
By Application
  • Therapeutic Applications
  • Research Applications
By End User
  • Blood Centers
  • Hospitals
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Terumo BCT, Inc., Fresenius Kabi, Adacyte Therapeutics, SB-Kawasumi Laboratories, Inc., Asahi Kasei Corporation, AllCells, LLC., Haemonetics Corporation, Cerus Corporation, Macopharma, Charles River Laboratories International, Inc.

Analyst Review

Leukapheresis procedures consume multiple disposable parts and such intensive consumption of disposables significantly contributes toward revenue generation. Moreover, single-use products curb the risk of infection, which is of high significance in leukapheresis as well as transfusion procedures.

The global leukapheresis market is expected to exhibit high growth potential attributable to factors such as increase in demand for blood components globally is expected to offer profitable opportunities for expansion of the market. In addition, therapeutic apheresis is majorly carried out among patients suffering from leukemia, which has piqued the interest of several companies to manufacture efficient and advanced apheresis systems.

Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in awareness toward blood donations and rise in government initiatives promoting blood donations drive the market growth. Surge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for manufacturing leukapheresis devices and disposables during the forecast period.
 

 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Low bargaining power of suppliers

      • 3.3.2. Low threat of new entrants

      • 3.3.3. Low threat of substitutes

      • 3.3.4. Low intensity of rivalry

      • 3.3.5. Low bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Increase in incidences and prevalence of leukemia.
        • 3.4.1.2. Increase in government initiatives toward blood donation.
        • 3.4.1.3. Increase in demand for leukopak

      • 3.4.2. Restraints

        • 3.4.2.1. High costs associated with leukapheresis therapeutics and leukopaks
        • 3.4.2.2. Blood transfusion safety in developing countries

      • 3.4.3. Opportunities

        • 3.4.3.1. Leukapheresis for pediatric patients

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Devices

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Disposables

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

  • CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Centrifugation

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Membrane Separation

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Selective Adsorption

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

  • CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Therapeutic Applications

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Research Applications

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

  • CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER

    • 7.1. Overview

      • 7.1.1. Market size and forecast

    • 7.2. Blood Centers

      • 7.2.1. Key market trends, growth factors and opportunities

      • 7.2.2. Market size and forecast, by region

      • 7.2.3. Market share analysis by country

    • 7.3. Hospitals

      • 7.3.1. Key market trends, growth factors and opportunities

      • 7.3.2. Market size and forecast, by region

      • 7.3.3. Market share analysis by country

    • 7.4. Others

      • 7.4.1. Key market trends, growth factors and opportunities

      • 7.4.2. Market size and forecast, by region

      • 7.4.3. Market share analysis by country

  • CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION

    • 8.1. Overview

      • 8.1.1. Market size and forecast By Region

    • 8.2. North America

      • 8.2.1. Key market trends, growth factors and opportunities

      • 8.2.2. Market size and forecast, by Product

      • 8.2.3. Market size and forecast, by Method

      • 8.2.4. Market size and forecast, by Application

      • 8.2.5. Market size and forecast, by End User

      • 8.2.6. Market size and forecast, by country

        • 8.2.6.1. U.S.
          • 8.2.6.1.1. Market size and forecast, by Product
          • 8.2.6.1.2. Market size and forecast, by Method
          • 8.2.6.1.3. Market size and forecast, by Application
          • 8.2.6.1.4. Market size and forecast, by End User
        • 8.2.6.2. Canada
          • 8.2.6.2.1. Market size and forecast, by Product
          • 8.2.6.2.2. Market size and forecast, by Method
          • 8.2.6.2.3. Market size and forecast, by Application
          • 8.2.6.2.4. Market size and forecast, by End User
        • 8.2.6.3. Mexico
          • 8.2.6.3.1. Market size and forecast, by Product
          • 8.2.6.3.2. Market size and forecast, by Method
          • 8.2.6.3.3. Market size and forecast, by Application
          • 8.2.6.3.4. Market size and forecast, by End User
    • 8.3. Europe

      • 8.3.1. Key market trends, growth factors and opportunities

      • 8.3.2. Market size and forecast, by Product

      • 8.3.3. Market size and forecast, by Method

      • 8.3.4. Market size and forecast, by Application

      • 8.3.5. Market size and forecast, by End User

      • 8.3.6. Market size and forecast, by country

        • 8.3.6.1. Germany
          • 8.3.6.1.1. Market size and forecast, by Product
          • 8.3.6.1.2. Market size and forecast, by Method
          • 8.3.6.1.3. Market size and forecast, by Application
          • 8.3.6.1.4. Market size and forecast, by End User
        • 8.3.6.2. France
          • 8.3.6.2.1. Market size and forecast, by Product
          • 8.3.6.2.2. Market size and forecast, by Method
          • 8.3.6.2.3. Market size and forecast, by Application
          • 8.3.6.2.4. Market size and forecast, by End User
        • 8.3.6.3. UK
          • 8.3.6.3.1. Market size and forecast, by Product
          • 8.3.6.3.2. Market size and forecast, by Method
          • 8.3.6.3.3. Market size and forecast, by Application
          • 8.3.6.3.4. Market size and forecast, by End User
        • 8.3.6.4. Italy
          • 8.3.6.4.1. Market size and forecast, by Product
          • 8.3.6.4.2. Market size and forecast, by Method
          • 8.3.6.4.3. Market size and forecast, by Application
          • 8.3.6.4.4. Market size and forecast, by End User
        • 8.3.6.5. Spain
          • 8.3.6.5.1. Market size and forecast, by Product
          • 8.3.6.5.2. Market size and forecast, by Method
          • 8.3.6.5.3. Market size and forecast, by Application
          • 8.3.6.5.4. Market size and forecast, by End User
        • 8.3.6.6. Rest of Europe
          • 8.3.6.6.1. Market size and forecast, by Product
          • 8.3.6.6.2. Market size and forecast, by Method
          • 8.3.6.6.3. Market size and forecast, by Application
          • 8.3.6.6.4. Market size and forecast, by End User
    • 8.4. Asia-Pacific

      • 8.4.1. Key market trends, growth factors and opportunities

      • 8.4.2. Market size and forecast, by Product

      • 8.4.3. Market size and forecast, by Method

      • 8.4.4. Market size and forecast, by Application

      • 8.4.5. Market size and forecast, by End User

      • 8.4.6. Market size and forecast, by country

        • 8.4.6.1. Japan
          • 8.4.6.1.1. Market size and forecast, by Product
          • 8.4.6.1.2. Market size and forecast, by Method
          • 8.4.6.1.3. Market size and forecast, by Application
          • 8.4.6.1.4. Market size and forecast, by End User
        • 8.4.6.2. China
          • 8.4.6.2.1. Market size and forecast, by Product
          • 8.4.6.2.2. Market size and forecast, by Method
          • 8.4.6.2.3. Market size and forecast, by Application
          • 8.4.6.2.4. Market size and forecast, by End User
        • 8.4.6.3. India
          • 8.4.6.3.1. Market size and forecast, by Product
          • 8.4.6.3.2. Market size and forecast, by Method
          • 8.4.6.3.3. Market size and forecast, by Application
          • 8.4.6.3.4. Market size and forecast, by End User
        • 8.4.6.4. Australia
          • 8.4.6.4.1. Market size and forecast, by Product
          • 8.4.6.4.2. Market size and forecast, by Method
          • 8.4.6.4.3. Market size and forecast, by Application
          • 8.4.6.4.4. Market size and forecast, by End User
        • 8.4.6.5. South Korea
          • 8.4.6.5.1. Market size and forecast, by Product
          • 8.4.6.5.2. Market size and forecast, by Method
          • 8.4.6.5.3. Market size and forecast, by Application
          • 8.4.6.5.4. Market size and forecast, by End User
        • 8.4.6.6. Rest of Asia-Pacific
          • 8.4.6.6.1. Market size and forecast, by Product
          • 8.4.6.6.2. Market size and forecast, by Method
          • 8.4.6.6.3. Market size and forecast, by Application
          • 8.4.6.6.4. Market size and forecast, by End User
    • 8.5. LAMEA

      • 8.5.1. Key market trends, growth factors and opportunities

      • 8.5.2. Market size and forecast, by Product

      • 8.5.3. Market size and forecast, by Method

      • 8.5.4. Market size and forecast, by Application

      • 8.5.5. Market size and forecast, by End User

      • 8.5.6. Market size and forecast, by country

        • 8.5.6.1. Brazil
          • 8.5.6.1.1. Market size and forecast, by Product
          • 8.5.6.1.2. Market size and forecast, by Method
          • 8.5.6.1.3. Market size and forecast, by Application
          • 8.5.6.1.4. Market size and forecast, by End User
        • 8.5.6.2. Saudi Arabia
          • 8.5.6.2.1. Market size and forecast, by Product
          • 8.5.6.2.2. Market size and forecast, by Method
          • 8.5.6.2.3. Market size and forecast, by Application
          • 8.5.6.2.4. Market size and forecast, by End User
        • 8.5.6.3. South Africa
          • 8.5.6.3.1. Market size and forecast, by Product
          • 8.5.6.3.2. Market size and forecast, by Method
          • 8.5.6.3.3. Market size and forecast, by Application
          • 8.5.6.3.4. Market size and forecast, by End User
        • 8.5.6.4. Rest of LAMEA
          • 8.5.6.4.1. Market size and forecast, by Product
          • 8.5.6.4.2. Market size and forecast, by Method
          • 8.5.6.4.3. Market size and forecast, by Application
          • 8.5.6.4.4. Market size and forecast, by End User
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top winning strategies

    • 9.3. Product Mapping of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top player positioning, 2021

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Adacyte Therapeutics

      • 10.1.1. Company overview

      • 10.1.2. Key Executives

      • 10.1.3. Company snapshot

      • 10.1.4. Operating business segments

      • 10.1.5. Product portfolio

    • 10.2. AllCells, LLC.

      • 10.2.1. Company overview

      • 10.2.2. Key Executives

      • 10.2.3. Company snapshot

      • 10.2.4. Operating business segments

      • 10.2.5. Product portfolio

    • 10.3. Asahi Kasei Corporation

      • 10.3.1. Company overview

      • 10.3.2. Key Executives

      • 10.3.3. Company snapshot

      • 10.3.4. Operating business segments

      • 10.3.5. Product portfolio

      • 10.3.6. Business performance

    • 10.4. Charles River Laboratories International, Inc.

      • 10.4.1. Company overview

      • 10.4.2. Key Executives

      • 10.4.3. Company snapshot

      • 10.4.4. Operating business segments

      • 10.4.5. Product portfolio

      • 10.4.6. Business performance

    • 10.5. Cerus Corporation

      • 10.5.1. Company overview

      • 10.5.2. Key Executives

      • 10.5.3. Company snapshot

      • 10.5.4. Operating business segments

      • 10.5.5. Product portfolio

    • 10.6. Fresenius Kabi

      • 10.6.1. Company overview

      • 10.6.2. Key Executives

      • 10.6.3. Company snapshot

      • 10.6.4. Operating business segments

      • 10.6.5. Product portfolio

    • 10.7. Haemonetics Corporation

      • 10.7.1. Company overview

      • 10.7.2. Key Executives

      • 10.7.3. Company snapshot

      • 10.7.4. Operating business segments

      • 10.7.5. Product portfolio

      • 10.7.6. Business performance

    • 10.8. Macopharma

      • 10.8.1. Company overview

      • 10.8.2. Key Executives

      • 10.8.3. Company snapshot

      • 10.8.4. Operating business segments

      • 10.8.5. Product portfolio

    • 10.9. SB-Kawasumi Laboratories, Inc.

      • 10.9.1. Company overview

      • 10.9.2. Key Executives

      • 10.9.3. Company snapshot

      • 10.9.4. Operating business segments

      • 10.9.5. Product portfolio

    • 10.10. Terumo BCT, Inc.

      • 10.10.1. Company overview

      • 10.10.2. Key Executives

      • 10.10.3. Company snapshot

      • 10.10.4. Operating business segments

      • 10.10.5. Product portfolio

      • 10.10.6. Business performance

  • LIST OF TABLES

  • TABLE 01. GLOBAL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 02. LEUKAPHERESIS MARKET FOR DEVICES, BY REGION, 2021-2031 ($MILLION)
    TABLE 03. LEUKAPHERESIS MARKET FOR DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
    TABLE 04. GLOBAL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 05. LEUKAPHERESIS MARKET FOR CENTRIFUGATION, BY REGION, 2021-2031 ($MILLION)
    TABLE 06. LEUKAPHERESIS MARKET FOR MEMBRANE SEPARATION, BY REGION, 2021-2031 ($MILLION)
    TABLE 07. LEUKAPHERESIS MARKET FOR SELECTIVE ADSORPTION, BY REGION, 2021-2031 ($MILLION)
    TABLE 08. GLOBAL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 09. LEUKAPHERESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
    TABLE 10. LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
    TABLE 11. GLOBAL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 12. LEUKAPHERESIS MARKET FOR BLOOD CENTERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 13. LEUKAPHERESIS MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
    TABLE 14. LEUKAPHERESIS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 15. LEUKAPHERESIS MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 16. NORTH AMERICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 17. NORTH AMERICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 18. NORTH AMERICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 19. NORTH AMERICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 20. NORTH AMERICA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 21. U.S. LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 22. U.S. LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 23. U.S. LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 24. U.S. LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 25. CANADA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 26. CANADA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 27. CANADA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 28. CANADA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 29. MEXICO LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 30. MEXICO LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 31. MEXICO LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 32. MEXICO LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 33. EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 34. EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 35. EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 36. EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 37. EUROPE LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 38. GERMANY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 39. GERMANY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 40. GERMANY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 41. GERMANY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 42. FRANCE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 43. FRANCE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 44. FRANCE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 45. FRANCE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 46. UK LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 47. UK LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 48. UK LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 49. UK LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 50. ITALY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 51. ITALY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 52. ITALY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 53. ITALY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 54. SPAIN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 55. SPAIN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 56. SPAIN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 57. SPAIN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 58. REST OF EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 59. REST OF EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 60. REST OF EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 61. REST OF EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 62. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 63. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 64. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 65. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 66. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 67. JAPAN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 68. JAPAN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 69. JAPAN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 70. JAPAN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 71. CHINA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 72. CHINA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 73. CHINA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 74. CHINA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 75. INDIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 76. INDIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 77. INDIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 78. INDIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 79. AUSTRALIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 80. AUSTRALIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 81. AUSTRALIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 82. AUSTRALIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 83. SOUTH KOREA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 84. SOUTH KOREA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 85. SOUTH KOREA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 86. SOUTH KOREA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 87. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 88. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 89. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 90. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 91. LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 92. LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 93. LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 94. LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 95. LAMEA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 96. BRAZIL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 97. BRAZIL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 98. BRAZIL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 99. BRAZIL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 100. SAUDI ARABIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 101. SAUDI ARABIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 102. SAUDI ARABIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 103. SAUDI ARABIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 104. SOUTH AFRICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 105. SOUTH AFRICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 106. SOUTH AFRICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 107. SOUTH AFRICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 108. REST OF LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 109. REST OF LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
    TABLE 110. REST OF LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 111. REST OF LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 112. ADACYTE THERAPEUTICS: KEY EXECUTIVES
    TABLE 113. ADACYTE THERAPEUTICS: COMPANY SNAPSHOT
    TABLE 114. ADACYTE THERAPEUTICS: PRODUCT SEGMENTS
    TABLE 115. ADACYTE THERAPEUTICS: PRODUCT PORTFOLIO
    TABLE 116. ALLCELLS, LLC.: KEY EXECUTIVES
    TABLE 117. ALLCELLS, LLC.: COMPANY SNAPSHOT
    TABLE 118. ALLCELLS, LLC.: PRODUCT SEGMENTS
    TABLE 119. ALLCELLS, LLC.: PRODUCT PORTFOLIO
    TABLE 120. ASAHI KASEI CORPORATION: KEY EXECUTIVES
    TABLE 121. ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
    TABLE 122. ASAHI KASEI CORPORATION: PRODUCT SEGMENTS
    TABLE 123. ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
    TABLE 124. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY EXECUTIVES
    TABLE 125. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
    TABLE 126. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: SERVICE SEGMENTS
    TABLE 127. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
    TABLE 128. CERUS CORPORATION: KEY EXECUTIVES
    TABLE 129. CERUS CORPORATION: COMPANY SNAPSHOT
    TABLE 130. CERUS CORPORATION: PRODUCT SEGMENTS
    TABLE 131. CERUS CORPORATION: PRODUCT PORTFOLIO
    TABLE 132. FRESENIUS KABI: KEY EXECUTIVES
    TABLE 133. FRESENIUS KABI: COMPANY SNAPSHOT
    TABLE 134. FRESENIUS KABI: PRODUCT SEGMENTS
    TABLE 135. FRESENIUS KABI: PRODUCT PORTFOLIO
    TABLE 136. HAEMONETICS CORPORATION: KEY EXECUTIVES
    TABLE 137. HAEMONETICS CORPORATION: COMPANY SNAPSHOT
    TABLE 138. HAEMONETICS CORPORATION: PRODUCT SEGMENTS
    TABLE 139. HAEMONETICS CORPORATION: PRODUCT PORTFOLIO
    TABLE 140. MACOPHARMA: KEY EXECUTIVES
    TABLE 141. MACOPHARMA: COMPANY SNAPSHOT
    TABLE 142. MACOPHARMA: PRODUCT SEGMENTS
    TABLE 143. MACOPHARMA: PRODUCT PORTFOLIO
    TABLE 144. SB-KAWASUMI LABORATORIES, INC.: KEY EXECUTIVES
    TABLE 145. SB-KAWASUMI LABORATORIES, INC.: COMPANY SNAPSHOT
    TABLE 146. SB-KAWASUMI LABORATORIES, INC.: PRODUCT SEGMENTS
    TABLE 147. SB-KAWASUMI LABORATORIES, INC.: PRODUCT PORTFOLIO
    TABLE 148. TERUMO BCT, INC.: KEY EXECUTIVES
    TABLE 149. TERUMO BCT, INC.: COMPANY SNAPSHOT
    TABLE 150. TERUMO BCT, INC.: PRODUCT SEGMENTS
    TABLE 151. TERUMO BCT, INC.: SERVICE SEGMENTS
    TABLE 152. TERUMO BCT, INC.: PRODUCT PORTFOLIO
  • LIST OF FIGURES

  • FIGURE 1.LEUKAPHERESIS MARKET SEGMENTATION
    FIGURE 2.LEUKAPHERESIS MARKET,2021-2031
    FIGURE 3.LEUKAPHERESIS MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.LEUKAPHERESIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.LEUKAPHERESIS MARKET,BY PRODUCT,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DEVICES LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DISPOSABLES LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 15.LEUKAPHERESIS MARKET,BY METHOD,2021(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CENTRIFUGATION LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MEMBRANE SEPARATION LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SELECTIVE ADSORPTION LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 19.LEUKAPHERESIS MARKET,BY APPLICATION,2021(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC APPLICATIONS LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RESEARCH APPLICATIONS LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 22.LEUKAPHERESIS MARKET,BY END USER,2021(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF BLOOD CENTERS LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS LEUKAPHERESIS MARKET,2021-2031(%)
    FIGURE 26.LEUKAPHERESIS MARKET BY REGION,2021
    FIGURE 27.U.S. LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 28.CANADA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 29.MEXICO LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 30.GERMANY LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 31.FRANCE LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 32.UK LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 33.ITALY LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 34.SPAIN LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 35.REST OF EUROPE LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 36.JAPAN LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 37.CHINA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 38.INDIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 39.AUSTRALIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 40.SOUTH KOREA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 41.REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 42.BRAZIL LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 43.SAUDI ARABIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 44.SOUTH AFRICA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 45.REST OF LAMEA LEUKAPHERESIS MARKET,2021-2031($MILLION)
    FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 50.COMPETITIVE DASHBOARD
    FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 52.ADACYTE THERAPEUTICS.: NET SALES ,($MILLION)
    FIGURE 53.ALLCELLS, LLC..: NET SALES ,($MILLION)
    FIGURE 54.ASAHI KASEI CORPORATION.: NET SALES ,($MILLION)
    FIGURE 55.CHARLES RIVER LABORATORIES INTERNATIONAL, INC..: NET SALES ,($MILLION)
    FIGURE 56.CERUS CORPORATION.: NET SALES ,($MILLION)
    FIGURE 57.FRESENIUS KABI.: NET SALES ,($MILLION)
    FIGURE 58.HAEMONETICS CORPORATION.: NET SALES ,($MILLION)
    FIGURE 59.MACOPHARMA.: NET SALES ,($MILLION)
    FIGURE 60.SB-KAWASUMI LABORATORIES, INC..: NET SALES ,($MILLION)
    FIGURE 61.TERUMO BCT, INC..: NET SALES ,($MILLION)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Leukapheresis is a laboratory procedure in which white blood cells are removed from a sample of blood and other blood cells and plasma back into the bloodstream

A. Top companies such as Fresenius Kabi, Haemonetics Corporation, Terumo BCT, Inc., Charles River Laboratories International, Inc. held high market share in 2021.

A. The disposables segment is the most influencing segment owing to rise in demand for leukapheresis procedures for isolation of white blood cells, which requires disposables

A. Increase in demand for blood donations, rise in prevenece of leukemia and rise in demand for leukopaks in clinical research studies responsible for the market growth

A. The market value of leukapheresis market in 2031 is $561.64 million.

A. The base year is 2021 in leukapheresis market.

A. The total market value of leukapheresis market is $245.65 million in 2021.

A. The forecast period for leukapheresis market is 2022 to 2031

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Leukapheresis Market

Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers